.svg){kind=small}
Oct-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Is this your brand?
See your full sales and distribution data: where you sell, how you're priced, and how you rank against the brands next to you on the shelf.
See your brand's dataCarry this brand in your store?
Headset Retailer is free. Connect your POS and see what's selling and what's sitting.
Sign up freeWhere to Buy
Remedi is stocked at 281 licensed dispensaries across Illinois, Pennsylvania, and 3 other states, 128 of them in Illinois, with the deepest coverage in Chicago, Normal, Springfield, Champaign, and East Peoria. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Remedi’s October 2026 mix concentrated 86.48% of sales in Concentrates with year-over-year growth of 48.17% and month-over-month growth of 14.31%, while Tincture & Sublingual held 12.23% share with 31.11% YoY and 5.34% MoM, and Capsules fell to 1.29% share with -61.37% YoY and -64.13% MoM. The brand’s overall sales were up 40.79% YoY alongside a -5.49% YoY average price shift, and in Concentrates the category rank in Illinois sat at 18; this mix signals a deliberate tilt toward higher-velocity formats where price elasticity is supporting volume at scale, while low-share Capsules are being deprioritized as an inefficient allocation.
The widening gap between Concentrates at 86.48% share and Tincture & Sublingual at 12.23%, combined with a -5.49% YoY price move and a 14.31% MoM lift in Concentrates, implies Remedi is trading price for placement to build throughput, anchoring its positioning toward value-access Concentrates rather than portfolio breadth. Holding rank 18 in Illinois Concentrates with 48.17% YoY and 31.11% YoY in Tincture & Sublingual suggests headroom remains if the brand sustains MoM momentum at 14.31% in the lead category while containing Capsule drag at -64.13% MoM; the strategic implication is to reinforce the Concentrates core and use Tincture & Sublingual as a secondary growth lane, treating Capsules as an exit or seasonal niche.
Competitive Landscape
Remedi is ranked #18 in Illinois Concentrates in October 2026, improving 6 positions year over year from #24 and edging up 1 position since July 2026 from #19, while its peak rank of #18 also lands in October 2026; in contrast, IC Collective advanced from #7 to #3 with 92.1% YoY sales growth and Cresco Labs moved from #13 to #5 on a 49.3% YoY increase, indicating that competitors are converting growth into larger rank jumps than Remedi’s 6-rank YoY gain and 1-rank quarter-over-quarter lift, which implies Remedi’s trajectory is upward but trailing the pace-setters’ acceleration.
Notable Products
Remedi’s October 2026 lineup is concentrated in RSO and related concentrates, with 86.5% of sales in the RSO / WPE / Full Spectrum segment and 97.1% coming from the top 10 items. Indica Relief RSO Syringe (0.5g) alone holds 23.0% share, so most of its sales ride on a tight set of RSO formats.
Peer avg: average price of the same product type and package size in the same states that month.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
